Research

Study: Lilly's Retatrutide Cuts Weight, Knee Pain and Sleep Apnea

Is this a breakthrough that finally treats obesity as a disease or a band aid ignoring underlying heart issues?

Published 1 day ago

Study: Lilly's Retatrutide Cuts Weight, Knee Pain and Sleep Apnea

story

Above: The Eli Lilly logo at the company's ceremony for its new facility in Houston, Texas, on Sept. 21. Image credit: Mark Felix/Bloomberg/Getty Images

The Spin

Pro-industry narrative

Obesity, diabetes and fatty liver are biological diseases, not moral failings, and hitting three metabolic pathways at once finally matches the size of the problem. Weight loss that deep, plus easier knees, quieter sleep apnea and blood sugar pushed back under the diabetes line, means fewer heart attacks, dialysis chairs and transplant lists. Medicine like this doesn't excuse lifestyle change — it makes it possible.

Beyond the White Coat on Substack Time

Industry-critical narrative

Dramatic weight-loss means nothing if the heart underneath keeps failing, and a trial where the sickest patients on the drug logged more cardiac events than those on placebo deserves hard answers, not a victory lap. The full safety picture, from pancreatitis to strange skin sensations, is still unknown. Meanwhile an unapproved peptide is being mixed at kitchen tables from sketchy vendors while regulators mail letters nobody fears.

Public Citizen

Alex Berenson on Substack